Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in Third-line Metastatic Gastric Cancer
NCT05342389Phase 2
Key facts
- Status
- Unknown
- Start
- May 2022
- Primary completion
- May 2023
- Countries
- 1
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- gastric adenocarcinomagastroesophageal junction adenocarcinoma
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Camrelizumab + Apatinib
Combination therapy arm
Apatinib Alone
Active comparator arm
03
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Objective Response Rate
Quality of Life
Toxicity
Beyond the preview
Go deeper on NCT05342389.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342389.